Apimeds Pharmaceuticals US (APUS) EBIT (2024 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported EBIT for 3 consecutive years, with -$6.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT fell 135.7% year-over-year to -$6.3 million; the trailing twelve-month figure through Jun 2026 stood at -$17.8 million (down 394.66% YoY), and the FY2025 full-year result was -$11.9 million, down 834.25% from the prior year.
• EBIT rose to -$6.3 million in Q2 2026 per APUS's latest filing, from -$7.0 million in the prior quarter.
• Across five years, EBIT topped out at -$271726.0 in Q1 2024 and bottomed at -$7.0 million in Q4 2025.
• Historically, EBIT has averaged -$2.2 million across 3 years, with a median of -$427757.0 in 2024.
• The widest YoY moves for EBIT: up 34.09% in 2025, down 2454.32% in 2025.
• Over 3 years, EBIT stood at -$275613.0 in 2024, then slumped by 2454.32% to -$7.0 million in 2025, then advanced by 10.81% to -$6.3 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$6.3 million, -$7.0 million, and -$1.8 million for Q2 2026, Q4 2025, and Q3 2025 respectively.